secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001641172-25-009155
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharmaceuticals to acquire SKNY; combined enterprise value over $60M
-------------------------------------------------------------------------

- Board unanimously approved definitive agreement to acquire SKNY on April 30, 2025.
- Third-party valuation assigned SKNY enterprise value of ~$30.5M; MIRA ~$30M.
- SKNY to contribute $5M in assets or cash at closing with no contingencies.
- Combined enterprise value exceeds $60M, creating a broader platform targeting obesity and nicotine dependence.
- MIRA preparing to file proxy statement to seek shareholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225009155/0001641172-25-009155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225009155/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer